Bristol Myers: FDA approval in lung cancer

(CercleFinance.com) - Bristol Myers Squibb announces that the US FDA has approved its Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).


This approval is based on the pivotal TRIDENT-1 trial, a single-arm, open-label Phase 1/2 trial in which Augtyro achieved a high objective response rate and durable response, the pharmaceutical company says.

Augtyro adds to Bristol Myers Squibb's growing and differentiated portfolio in NSCLC, expanding the company's presence in precision medicine, the healthcare group points out.


Copyright (c) 2023 CercleFinance.com. All rights reserved.